Valuation: Polaryx Therapeutics, Inc.

Market Cap 10Cr 9.16Cr 8.57Cr 7.77Cr 15Cr 994.65Cr 15Cr 102.95Cr 40Cr 507.41Cr 39Cr 38Cr 1.63TCr P/E 2026 *
-10.6x
P/E 2027 * -7.2x
Enterprise Value 10Cr 9.16Cr 8.57Cr 7.77Cr 15Cr 994.65Cr 15Cr 102.95Cr 40Cr 507.41Cr 39Cr 38Cr 1.63TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+1.45%
1 week+1.45%
Current month+1.45%
1 month+3.96%
3 months-20.75%
6 months-63.35%
1 week 1.96
Extreme 1.965
2.15
1 month 1.96
Extreme 1.965
2.2
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 01/03/2023
Director of Finance/CFO 60 01/06/2024
Chief Tech/Sci/R&D Officer 56 01/09/2026
Director TitleAgeSince
Chairman 56 01/06/2021
Director/Board Member 60 01/08/2025
Director/Board Member - 29/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Buy

Chief Executive Officer

88,453 0.1868%
18/02/26 Buy

Chief Financial Officer

2,867 -
29/01/26 Other

Chief Financial Officer

2,25,358 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+1.45% - - 10Cr
+4.16%+3.42%+49.37%+94.17% 7.43TCr
+2.76%-1.16%+23.05%+83.03% 5.7TCr
+0.24%-1.37%+4.08%+37.22% 4.83TCr
-3.76%-2.25%+329.09%+698.20% 4.45TCr
-2.30%-3.35%+26.81%+30.88% 4.38TCr
+0.31%-0.68%+5.30%+108.64% 4.11TCr
-0.11%+2.30%+9.19%+58.68% 3.11TCr
+4.51%+8.43%+37.27%+34.97% 2.9TCr
-1.96%-2.88%-8.97%-13.92% 2.45TCr
Average +0.45%-0.04%+52.80%+125.76% 3.94TCr
Weighted average by Cap. +0.67%-0.50%+56.83%+134.46%

Financials

2026 *2027 *
Net sales - -
Net income -91.64L -81.35L -76.13L -69L -1.3Cr -88Cr -1.31Cr -9.14Cr -3.56Cr -45Cr -3.44Cr -3.37Cr -144.88Cr -1.64Cr -1.46Cr -1.36Cr -1.24Cr -2.34Cr -158.33Cr -2.35Cr -16Cr -6.37Cr -81Cr -6.17Cr -6.03Cr -259.67Cr
Net Debt - -
Projected Income Statement - Annual - Polaryx Therapeutics, Inc.
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
07/26/07 $2.100 +1.45% 5,532
05/26/05 $2.070 -0.48% 40,067
02/26/02 $2.080 +2.97% 20,768
01/26/01 $2.020 -2.42% 58,969
30/26/30 $2.070 0.00% 16,582
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Polaryx Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.070USD
Average target price
7.500USD
Spread / Average Target
+262.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Polaryx Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLYX Stock